Seroatlas · Human Serome Atlas

PMP22

Peripheral myelin protein 22

Also known as: CMT1A, GAS3, HMSNIA, HNPP, PMP22_HUMAN, Sp110

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q01453
Gene
PMP22
Ensembl
ENSG00000109099
Chromosome
17
Canonical length
160 aa
Protein class
Cancer-related genes, Disease related genes, Human disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters

OverviewNCBI Gene

This gene encodes an integral membrane protein that is a major component of myelin in the peripheral nervous system. Studies suggest two alternately used promoters drive tissue-specific expression. Various mutations of this gene are causes of Charcot-Marie-Tooth disease Type IA, Dejerine-Sottas syndrome, and hereditary neuropathy with liability to pressure palsies. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]

Canonical amino-acid sequenceUniProt

160 residues, UniProt reviewed canonical sequence.

>Q01453|PMP22
     1  MLLLLLSIIV LHVAVLVLLF VSTIVSQWIV GNGHATDLWQ NCSTSSSGNV HHCFSSSPNE
    61  WLQSVQATMI LSIIFSILSL FLFFCQLFTL TKGGRFYITG IFQILAGLCV MSAAAIYTVR
   121  HPEWHLNSDY SYGFAYILAW VAFPLALLSG VIYVILRKRE

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PMP22 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
4
Mean surface accessibility (rSASA)
0.29
Highest tissue expression
246 nTPM

Expression across tissuesHPA

Tissue

  • adipose tissue: 246 nTPM
  • spinal cord: 230 nTPM
  • small intestine: 225 nTPM
  • urinary bladder: 195 nTPM
  • placenta: 190 nTPM
  • colon: 187 nTPM

Single-cell type

  • schwann cells: 1,578 nCPM
  • hofbauer cells: 1,290 nCPM
  • enterocytes: 1,064 nCPM
  • fibroblasts: 459 nCPM
  • melanocytes: 443 nCPM
  • decidual stromal cells: 388 nCPM

Immune cell

  • eosinophil: 43 nTPM
  • basophil: 32 nTPM
  • plasmacytoid DC: 24 nTPM
  • myeloid DC: 7.6 nTPM
  • classical monocyte: 1.4 nTPM
  • intermediate monocyte: 0.9 nTPM

Brain region

  • white matter: 311 nTPM
  • medulla oblongata: 213 nTPM
  • basal ganglia: 202 nTPM
  • cerebellum: 191 nTPM
  • midbrain: 171 nTPM
  • pons: 165 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PMP22.

Disease | AllUniProt

Conditions PMP22 is implicated in, by any mechanism.

Disease | GeneticClinVar

104 pathogenic / likely-pathogenic of 433 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

ReferencesPubMed · IEDB

Publications for PMP22 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

4 publications

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.39
gnomAD pLI
0.91
gnomAD missense Z
0.42
DepMap mean gene effect
0.06
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PMP22 as an antibody target. Whether an autoantibody or antibody against PMP22 could matter depends on whether native PMP22 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PMP22 is annotated at the cell surface, where native PMP22 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label PMP22 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PMP22. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...